Real-Life Cefiderocol Use in Bone and Joint Infection: A French National Cohort

<b>Background</b>: Cefiderocol (CFD) is a novel siderophore cephalosporin developed for the treatment of infections involving multidrug-resistant (MDR) Gram-negative bacilli (GNB) infections (1–3). For bone and joint infections (BJIs), the use of CFD is currently neither part of its market authoriza...

Descripció completa

Dades bibliogràfiques

Autors principals:	Ava Diarra, Maxime Degrendel, Isabelle Eberl, Tristan Ferry, Karim Jaffal, Lelia Escaut, Antoine Asquier Khati, Nicolas Taar, Johan Courjon, Laurène Deconinck, Benjamin Lefevre, Aurélie Baldolli, Messaline Bermejo, Alexandre Bleibtreu, Vincent Dacquet, Victoire de Lastours, Pierre Gazeau, Romaric Larcher, Pierre Patoz, Olivier Robineau, Nicolas Rouzic, Naomi Sayre, Diana Isabela Costescu Strachinaru, Benjamin Valentin, Heidi Wille, Eric Senneville
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2025-04-01
Col·lecció:	Antibiotics
Matèries:	cefiderocol bone and joint infection Gram-negative bacilli tolerance outcome
Accés en línia:	https://www.mdpi.com/2079-6382/14/4/388
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!